RORoivant Sciences ROIV NASDAQ · Healthcare · United Kingdom
$38.66 -0.78% -$0.31
- Market cap
- $28.2B
- Enterprise value
- $26.7B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 687.1x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -38.1%
- Gross margin
- 88.7%
- Net margin
- -838.2%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.20
- Free float
- 79.0%
About the company
Roivant Sciences (ROIV) is a biotechnology company specializing in the development and commercialization of innovative drugs and therapies. Utilizing advanced technologies and a strategic approach to research and development, Roivant Sciences focuses on rapidly bringing new treatment options to market. The company is known for its unique model and portfolio, which includes various therapeutic areas. Roivant Sciences is also engaged in partnerships with other organizations to accelerate healthcare innovations. Roivant Sciences (ROIV) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on innovation and research.
Sector
Healthcare
Industry
Biotechnology
CEO
Matthew Gline
Employees
721
Headquarters
London
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Analysts expect revenue to grow by 1,811% this fiscal year.
- What to watch: Revenue fell by 36% a year over the last 3 years.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $1.64B against $106.6M.
- What to watch: It passes only 2 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number